Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

277 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Successful Treatment of Unresectable BRCA1 L63*-Mutated Basal Cell Carcinoma Invading the Parietal Bone with Cisplatin and Fluorouracil: A Case Report.
Yoshida-Akai S, Fujimura T, Amagai R, Kambayashi Y, Hashimoto A, Terui H, Oka K, Watanabe-Takahashi M, Yamazaki E, Ohuchi K, Asano Y. Yoshida-Akai S, et al. Among authors: yamazaki e. Case Rep Oncol. 2024 Sep 20;17(1):1050-1054. doi: 10.1159/000541160. eCollection 2024 Jan-Dec. Case Rep Oncol. 2024. PMID: 39474537 Free PMC article.
Efficacy and safety of TM5614 in combination with paclitaxel in the treatment of paclitaxel-resistant cutaneous angiosarcoma: Phase II study protocol.
Fujimura T, Yoshino K, Nakamura M, Kato H, Ito T, Maekawa T, Fujisawa Y, Matsushita S, Amagai R, Yamazaki E, Takahashi M, Tamabuchi E, Hashimoto A, Kambayashi Y, Yamazaki N, Miyata T, Asano Y. Fujimura T, et al. Among authors: yamazaki n, yamazaki e. Exp Dermatol. 2024 Jan;33(1):e14976. doi: 10.1111/exd.14976. Epub 2023 Nov 9. Exp Dermatol. 2024. PMID: 37946551
A phase II multicentre study of plasminogen activator inhibitor-1 inhibitor (TM5614) plus nivolumab for treating anti-programmed cell death 1 antibody-refractory malignant melanoma: TM5614-MM trial.
Fujimura T, Yoshino K, Kato H, Fukushima S, Ishizuki S, Otsuka A, Matsushita S, Amagai R, Muto Y, Yamazaki E, Kambayashi Y, Yahata T, Miyata T, Fujisawa Y, Asano Y. Fujimura T, et al. Among authors: yamazaki e. Br J Dermatol. 2024 Oct 17;191(5):691-697. doi: 10.1093/bjd/ljae231. Br J Dermatol. 2024. PMID: 38833158 Clinical Trial.
277 results